Belsomra VA Coverage Pathway: How Veterans Can Access Suvorexant

What Suvorexant Is and Why Veterans May Need It

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting orexin-A and orexin-B neuropeptides. The FDA approved it in August 2014 for insomnia characterized by difficulty with sleep onset and sleep maintenance [1]. Unlike benzodiazepine receptor agonists, DORAs do not act on GABA pathways, which gives them a distinct safety profile regarding respiratory depression and abuse potential [2].

Insomnia prevalence among U.S. Veterans significantly exceeds the civilian population. A 2019 analysis of over 4.5 million VA electronic health records found that insomnia diagnoses increased 45% between 2010 and 2015, with rates highest among veterans with comorbid PTSD, traumatic brain injury, and chronic pain [3]. The VA/DoD Clinical Practice Guideline for chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment [4], but pharmacotherapy remains necessary for many veterans who cannot access CBT-I or who have insufficient response to it.

Suvorexant may hold particular relevance in this population. A 2020 randomized controlled trial (N=56) found that suvorexant reduced PTSD-related nightmares and improved overall sleep quality in military veterans compared to placebo [5]. The orexin system's role in arousal regulation makes DORAs a mechanistically appealing option for hyperarousal-driven insomnia common in veteran patients [6].

VA Formulary Status and Step-Therapy Requirements

Suvorexant is classified as a non-formulary medication within the VA National Formulary system. This means VA providers cannot prescribe it as a first-line sleep agent without meeting specific criteria. The VA Pharmacy Benefits Management (PBM) service manages formulary decisions, and non-formulary access requires documentation of clinical need.

Before a veteran can receive suvorexant, most VA medical centers require documented failure, intolerance, or contraindication to at least one formulary-preferred agent. Common required step-therapy trials include:

• Trazodone (50 to 150 mg at bedtime), the most widely prescribed sleep medication in the VA system
• Hydroxyzine (25 to 50 mg at bedtime), often used when sedating antihistamine properties are appropriate
• Prazosin (1 to 15 mg at bedtime), specifically for PTSD-associated nightmares per the VA/DoD PTSD Clinical Practice Guideline

A 2021 VA PBM drug class review noted that suvorexant and lemborexant should be reserved for patients who have not responded to preferred agents or who have contraindications to them [7]. "Failure" typically means an adequate trial of at least 2 to 4 weeks at therapeutic doses without clinically meaningful improvement in sleep onset latency or total sleep time.

How to Submit a Non-Formulary Drug Request

The non-formulary request process is the primary pathway for veterans to access suvorexant within the VA. Here is the step-by-step process.

Step 1: Discuss with your VA provider. Your primary care physician or psychiatrist initiates the request. Bring documentation of prior medication trials, including dates, doses, duration, and reasons for discontinuation. A sleep study may strengthen the clinical case, though it is not always mandatory [8].

Step 2: Provider completes VA Form 10-0457. This is the non-formulary drug request form. The provider must document the clinical rationale, specify which formulary alternatives were tried, and explain why suvorexant is medically necessary for the individual patient.

Step 3: Local pharmacy committee review. Each VA medical center has a Pharmacy and Therapeutics (P&T) committee that reviews non-formulary requests. The VA PBM Academic Detailing Service publishes criteria that local committees use as guidance, though individual facilities may have additional requirements [9]. Approval timelines vary by facility but typically range from 5 to 15 business days.

Step 4: If approved, prescription is filled. The medication is dispensed through the VA pharmacy at no copay or at the standard VA prescription copay tier. As of 2026, veterans in Priority Groups 1 through 6 pay $0 for prescriptions, while Priority Groups 7 and 8 pay a tiered copay of $5 for a 30-day supply of non-formulary medications under the VA copay structure.

Step 5: If denied, appeal or explore alternatives. Denials can be appealed through the facility's Patient Advocate office. The provider may also submit additional clinical documentation supporting the request.

Clinical Evidence Supporting VA Access Requests

Strong clinical documentation improves approval odds. The key registration trials provide the evidence base that P&T committees evaluate.

The phase III trial by Herring et al. (2012), a randomized, double-blind, placebo-controlled study of 781 patients, demonstrated that suvorexant significantly improved subjective total sleep time (sTST) and subjective wake after sleep onset (sWASO) at week 4 compared to placebo [10]. Mean sTST increased by 25 minutes with suvorexant 20 mg versus 12 minutes with placebo.

A longer-duration trial (N=1,021) published in Neurology confirmed sustained efficacy and safety over 12 months of nightly suvorexant use without evidence of rebound insomnia or withdrawal symptoms upon discontinuation [11]. This long-term data is relevant because VA providers often need to justify ongoing prescriptions at annual medication reconciliation reviews.

For the veteran-specific context, the randomized trial by Schipper et al. (2020) in military veterans with PTSD and comorbid insomnia showed suvorexant 20 mg significantly reduced nightmare frequency and improved Pittsburgh Sleep Quality Index (PSQI) global scores compared to placebo over 12 weeks [5]. The Clinician-Administered PTSD Scale (CAPS-5) sleep disturbance subscale also improved. This data directly supports formulary exception requests for veterans with PTSD-related sleep disturbance.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia conditionally recommends suvorexant for sleep maintenance insomnia in adults [12]. The guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults."

Cost Field Outside the VA

Veterans who cannot obtain suvorexant through the VA, or who receive care outside the VA system, face a steeper cost structure. The average retail cash price for a 30-day supply of Belsomra hovers around $85 as of mid-2026, though prices vary by pharmacy.

Manufacturer savings program. Merck offers a Belsomra savings card that can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 per fill, with maximum annual benefits specified in the program terms. This card is not available to patients covered by Medicare, Medicaid, TRICARE, or VA benefits per federal anti-kickback regulations [13].

Merck Patient Assistance Program. Uninsured or underinsured veterans who do not qualify for VA benefits may be eligible for free medication through the Merck Helps Patient Assistance Program. Income thresholds typically require household income at or below 400% of the federal poverty level [14].

Generic status. As of 2026, generic suvorexant has not yet reached the U.S. Market. Merck's patent protections on suvorexant have been the subject of ongoing litigation. Veterans should check the FDA Orange Book periodically for updated patent and exclusivity information [15].

GoodRx and discount cards. Third-party discount programs may reduce the cash price below $85 at select pharmacies. These programs operate independently and do not constitute insurance. They cannot be combined with VA benefits.

Suvorexant vs. Other VA-Available Sleep Medications

Understanding how suvorexant compares to formulary alternatives helps veterans and their providers build a stronger non-formulary request. Each comparison highlights a scenario where suvorexant may be clinically preferable.

Suvorexant vs. Trazodone. Trazodone is the most prescribed sleep agent in the VA system. It is effective, inexpensive, and well-studied. A 2017 systematic review noted that trazodone's evidence base for insomnia consists primarily of small, short-duration trials [16]. Common adverse effects include orthostatic hypotension, morning sedation, and priapism risk in male patients. Veterans who experience intolerable next-day drowsiness or cardiovascular side effects with trazodone have a documented basis for requesting suvorexant.

Suvorexant vs. Zolpidem. Zolpidem is available on some VA formularies as a restricted agent. The FDA issued a safety communication in 2013 requiring lower recommended doses due to next-morning impairment, particularly in women [17]. Complex sleep behaviors (sleepwalking, sleep-driving) led to an additional FDA boxed warning in 2019 [18]. Suvorexant carries a lower reported incidence of complex sleep behaviors in clinical trials [11], which may be relevant for veterans in safety-sensitive occupations.

Suvorexant vs. Lemborexant. Lemborexant (Dayvigo) is another DORA that received FDA approval in December 2019. A head-to-head trial (SUNRISE-2, N=949) comparing lemborexant and zolpidem showed lemborexant maintained efficacy at 6 months while zolpidem efficacy declined [19]. Neither suvorexant nor lemborexant is on the VA National Formulary as of 2026. If a VA facility covers one DORA but not the other, the alternative may be accessible through a simpler formulary substitution rather than a full non-formulary request.

Suvorexant vs. Prazosin. Prazosin targets nightmare-specific sleep disturbance in PTSD. The PRAZO trial (N=304) showed mixed results, with prazosin failing to separate from placebo on the primary outcome in the intention-to-treat analysis [20]. Veterans with PTSD-related insomnia who do not respond to prazosin may benefit from suvorexant's distinct mechanism of blocking orexin-mediated hyperarousal.

TRICARE and Community Care Pathways

Veterans eligible for VA Community Care may obtain suvorexant from non-VA providers under certain conditions. If a veteran is authorized for community care and the outside provider prescribes suvorexant, the prescription may be filled at a non-VA pharmacy with VA covering the cost. The same non-formulary criteria apply. The veteran's VA care team must coordinate authorization.

TRICARE beneficiaries (active-duty family members, retirees) follow a separate formulary managed by the Department of Defense Pharmacoeconomic Center. TRICARE classifies suvorexant as a non-formulary agent requiring prior authorization. The required documentation parallels the VA process: documented trial and failure of preferred agents, clinical rationale, and provider attestation. TRICARE mail-order through Express Scripts may offer lower cost-sharing than retail pharmacy fills once prior authorization is obtained.

Safety Considerations for Veteran Populations

The FDA prescribing information for suvorexant lists the most common adverse reactions as somnolence (7% vs. 3% placebo), headache, and dizziness [21]. Suvorexant is a Schedule IV controlled substance due to theoretical abuse potential, though post-marketing surveillance data and a 2018 analysis suggest abuse rates are lower than those observed with zolpidem or benzodiazepines [22].

For veterans taking opioids for chronic pain, the sedative interaction risk is lower with suvorexant than with benzodiazepines. The FDA black box warning on concurrent benzodiazepine-opioid use does not extend to DORAs [23], though additive CNS depression remains possible, and dose adjustments may be needed. Start at 5 mg or 10 mg in patients taking concurrent CNS depressants.

Veterans with moderate hepatic impairment should use a maximum dose of 10 mg [21]. Suvorexant is contraindicated in patients with narcolepsy. The recommended starting dose for all adults is 10 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining.